Search

Your search for "pcsa" returned the following results.
Filter Results:
InvestorNewsBreaks

InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) to Present at Biotech Showcase

January 4, 2023

Processa Pharmaceuticals (NASDAQ: PCSA), a diversified clinical-stage company developing products to improve survival and/or the quality of life for patients with unmet medical need conditions, today announced that its CEO Dr. David Young will present an update on Processa’s future therapeutic focus and strategy at the upcoming Biotech Showcase. The presentation is scheduled to begin […]

InvestorNewsBreaks

InvestorNewsBreaks – Processa Pharmaceuticals Inc.’s (NASDAQ: PCSA) PCS12852 Demonstrates Clinically Meaningful Improvements in Gastroparesis Symptoms

December 14, 2022

Processa Pharmaceuticals (NASDAQ: PCSA), a diversified clinical-stage company developing products to improve survival and/or the quality of life for patients with unmet medical need conditions, today announced positive top-line results on the clinical symptoms associated with gastroparesis from a 4-week Phase 2A study of PCS12852. The randomized, dose-response study for the treatment of patients with […]

InvestorNewsBreaks

InvestorNewsBreaks – Processa Pharmaceuticals Inc.’s (NASDAQ: PCSA) PCS12852 Demonstrates Improved Gastric Emptying in Phase 2A Trial

November 8, 2022

Processa Pharmaceuticals (NASDAQ: PCSA), a diversified clinical-stage company developing products to improve survival and/or the quality of life for patients who have an unmet medical need condition, today announced positive results from its PCS12852 Phase 2A trial in patients with moderate to severe gastroparesis. The four-week placebo-controlled, randomized, dose-response trial was designed to evaluate the […]

InvestorNewsBreaks

InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) to Host Conference Call to Discuss Q3 2022 Results, Provide Pipeline Update

November 2, 2022

Processa Pharmaceuticals (NASDAQ: PCSA), a clinical-stage biopharmaceutical company developing products to improve the survival and/or quality of life for patients with unmet medical need conditions, today announced that it will host a conference call and live webcast at 4:30 p.m. ET on Nov. 8, 2022, to discuss its third quarter 2022 results and provide an […]

InvestorNewsBreaks

InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Reports Successful Results from NGC Phase 2B Trial

November 1, 2022

Processa Pharmaceuticals (NASDAQ: PCSA), a diversified clinical-stage company developing products to improve survival and/or the quality of life for patients who have an unmet medical need conditions, is reporting positive results from its ongoing Next-Generation Capecitabine (“NGC”) phase 1B trial. According to the company, the trial indicates that NGC dosage regimens may have potential better […]

InvestorNewsBreaks

InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Shares Update on Clinical Programs Enrollment

September 15, 2022

Processa Pharmaceuticals (NASDAQ: PCSA), a clinical stage biopharmaceutical company focused on developing products to improve survival and/or quality of life for patients who have an unmet medical need condition for which there are few or no therapeutic options, has released update information regarding its clinical programs. Specifically, the updates provided information regarding enrollment for the […]

InvestorNewsBreaks

InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) to Participate at Upcoming Global Investment Conference

September 7, 2022

Processa Pharmaceuticals (NASDAQ: PCSA), a clinical stage biopharmaceutical company developing products to improve the survival and/or quality of life for patients who have an unmet medical need condition, will be part of the 22nd annual H.C. Wainwright Global Investment Conference. Processa Pharmaceuticals CEO Dr. David Young will be presenting at the event, which is scheduled […]

InvestorNewsBreaks

InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Names New Key Board Appointments

August 16, 2022

Processa Pharmaceuticals (NASDAQ: PCSA), a clinical-stage company developing drugs for patients who have unmet medical conditions that require better treatment options to improve a patient’s survival and/or quality of life, has announced new board appointments. The company named Khoso Baluch and James Neal to its board of directors and appointed current board member Justin Yorke […]

InvestorNewsBreaks

InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Releases Q2 2022 Results, Corporate Updates

August 12, 2022

Processa Pharmaceuticals (NASDAQ: PCSA), a clinical-stage company developing drugs for patients who have unmet medical conditions that require better treatment options to improve a patient’s survival and/or quality of life, is reporting financial numbers and clinical program updates for the quarter ended June 30, 2022. Highlights of the report include news that PCSA’s PCS12852  program is […]

InvestorNewsBreaks

InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Announces Q2 2022 Results Conference Call

August 8, 2022

Processa Pharmaceuticals (NASDAQ: PCSA), a clinical-stage company developing drugs for patients who have unmet medical conditions that require better treatment options to improve a patient’s survival and/or quality of life, has scheduled a conference call and webcast to discuss its second-quarter 2022 results; company executives will also provide an update on PCSA’s clinical pipeline during […]

InvestorNewsBreaks

InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Launches New Website Focused on Rare Disease

August 4, 2022

Processa Pharmaceuticals (NASDAQ: PCSA), a clinical-stage company developing drugs for patients who have unmet medical conditions that require better treatment options to improve a patient’s survival and/or quality of life, has released a new website: Necrobiosislipoidicastudy.com. Through the new website, the company is working to increase awareness of ulcerative Necrobiosis Lipoidica (“uNL”), an extremely rare […]

InvestorNewsBreaks

InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) CEO to Present at World Orphan Drug Congress USA

July 12, 2022

Processa Pharmaceuticals (NASDAQ: PCSA), a clinical-stage biopharmaceutical company developing drugs to improve the survival and/or quality of life for patients who have unmet medical conditions, has announced that its CEO Dr. David Young will present at the World Orphan Drug Congress USA 2022 Conference. Dr. Young’s presentation, “Thinking Regulatory First – Considerations for the Effective […]

InvestorNewsBreaks

InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Releases Q1 2022 Report, Updates

May 13, 2022

Processa Pharmaceuticals (NASDAQ: PCSA), a clinical-stage company developing drugs for patients who have unmet medical conditions that require better treatment options to improve a patient’s survival and/or quality of life, is reporting its financial results for the quarter ended March 31, 2022; the company also released an update on its clinical programs. According to the […]

InvestorNewsBreaks

InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) to Host Conference Call to Discuss Q1 2022 Results, Provide Drug Development Update

May 5, 2022

Processa Pharmaceuticals (NASDAQ: PCSA), a clinical-stage biopharmaceutical company developing products to improve the survival and/or quality of life for patients with unmet medical needs, today announced that it will host a conference call and live webcast at 4:30 p.m. ET on May 12, 2022, to discuss its results for the first quarter and provide an […]

InvestorNewsBreaks

InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Administers First Dosage in Amended Phase 1B Study

April 20, 2022

Processa Pharmaceuticals (NASDAQ: PCSA), a clinical-stage biopharmaceutical company developing products to improve the survival and/or quality of life for patients who have unmet medical need conditions, has started its amended maximum-tolerated dose (“MTD”) phase 1B trial for Next Generation Capecitabine, or the combination of PCS6422 and capecitabine. The company announced that the first patient, who […]

InvestorNewsBreaks

InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Enrolls First Patient in PCS12852 Phase 2A Trial

April 5, 2022

Processa Pharmaceuticals (NASDAQ: PCSA), a clinical-stage biopharmaceutical company developing products to improve the survival and/or quality of life for patients with unmet medical needs, today announced that it has enrolled its first patient in the Phase 2A clinical trial of PCS12852 in patients with moderate to severe gastroparesis. A chronic gastric motility disorder in which […]

InvestorNewsBreaks

InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Releases Year-End 2021 Financial, Corporate Results

March 31, 2022

Processa Pharmaceuticals (NASDAQ: PCSA), a clinical stage company developing drugs for patients who have unmet medical conditions that require better treatment options to improve survival and/or quality of life, has reported its financial numbers and corporate highlights for 2021 year end. Highlights of the report included the success of the company’s next-generation capecitabine Phase 1B […]

InvestorNewsBreaks

InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) to Host Conference Call to Discuss Q4 2021 Results, Provide Clinical Pipeline Update

March 23, 2022

Processa Pharmaceuticals (NASDAQ: PCSA), a clinical-stage biopharmaceutical company developing products to improve the survival and/or quality of life for patients with unmet medical need conditions, today announced that it will host a conference call and live webcast at 4:30 p.m. ET on March 30, 2022, to discuss its fourth quarter 2021 results and provide an […]

InvestorNewsBreaks

InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) CEO to Present at Oppenheimer 32nd Annual Healthcare Conference

March 10, 2022

Processa Pharmaceuticals (NASDAQ: PCSA), a clinical-stage biopharmaceutical company developing products to improve the survival and/or quality of life for patients with unmet medical need conditions, today announced that its CEO Dr. David Young will present at the Oppenheimer 32nd Annual Healthcare Conference. Dr. Young’s presentation is slated to begin at 10:00 a.m. Eastern Time on […]

InvestorNewsBreaks

InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Issues Letter to Shareholders Eyeing ‘Transformative Year’ in 2022

January 26, 2022

Processa Pharmaceuticals (NASDAQ: PCSA), a clinical-stage company developing drugs for patients who have unmet medical conditions that require better treatment options to improve a patient’s survival and/or quality of life, today released a letter to shareholders from its Chief Executive Officer Dr. David Young. In the letter, Dr. Young shared 2021 accomplishments and the company’s […]

InvestorNewsBreaks

InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Releases Q3 2021 Financial, Corporate Results

November 12, 2021

Processa Pharmaceuticals (NASDAQ: PCSA), a clinical stage company developing drugs for patients who have unmet medical conditions that require better treatment options to improve survival and/or quality of life, has reported its financial numbers and corporate highlights for third quarter 2021. Included in the report was results of the company’s next-generation capecitabine phase 1B trial, […]

InvestorNewsBreaks

InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Announces Results of Next-Generation Capecitabine Analysis

November 4, 2021

Processa Pharmaceuticals (NASDAQ: PCSA), a clinical-stage biopharmaceutical company developing products to improve the survival and quality of life for patients who have unmet medical needs, has released information regarding its next-generation capecitabine study. According to the company, the next-generation capecitabine dosage regimen, which is a combination of PCS6422 administered with capecitabine, successfully inhibited dihydropyrimidine dehydrogenase […]

InvestorNewsBreaks

InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) to Host Q3 Results, Development Update Call

October 26, 2021

Processa Pharmaceuticals (NASDAQ: PCSA), a clinical-stage biopharmaceutical company developing products to improve the survival and/or quality of life for patients with unmet medical needs, today announced that it will report financial results for the quarter ended Sept. 30, 2021, on Thursday, Nov. 11, 2021. According to the update, the company will host a conference call […]

InvestorNewsBreaks

InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Announces Key Milestone in Clinical Develop Program for PCS12852

October 12, 2021

Processa Pharmaceuticals (NASDAQ: PCSA), a clinical-stage biopharmaceutical company developing products to improve the survival and/or quality of life for patients with unmet medical needs, today announced that it has been cleared by the U.S. Food and Drug Administration (“FDA”) to proceed with a phase 2a clinical trial of PCS12852. The trial will study PCS12852 in […]

InvestorNewsBreaks

InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Announces Participation in Upcoming Investor Conferences

September 16, 2021

Processa Pharmaceuticals (NASDAQ: PCSA), a clinical-stage biopharmaceutical company developing products to improve the survival and/or quality of life for patients with unmet medical needs, today announced that management will participate in upcoming investor conferences. According to the update, PCSA will present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit starting at 9:05 a.m. […]

InvestorNewsBreaks

InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Announces Participation at World Orphan Drug Congress USA

August 24, 2021

Processa Pharmaceuticals (NASDAQ: PCSA), a clinical-stage biopharmaceutical company developing products to improve the survival and quality of life for patients who have unmet medical needs, will be presenting at the World Orphan Drug Congress USA Conference. The three-day event is scheduled for Aug. 25-27. Processa CEO and chair Dr. David Young will be the company […]

InvestorNewsBreaks

InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Releases Q2 Earnings, Schedules Earnings Call

August 13, 2021

Processa Pharmaceuticals (NASDAQ: PCSA), a clinical-stage biopharmaceutical company developing products to improve the survival and quality of life for patients who have unmet medical needs, has announced its financial results for Q2 2021, the quarter ended June 30, 2021. The company also shared a corporate update. Highlights of the report include that Processa dosed its […]

InvestorNewsBreaks

InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Announces Aug. 12 Earnings, Update Conference Call

August 6, 2021

Processa Pharmaceuticals (NASDAQ: PCSA), a clinical-stage biopharmaceutical company developing products to improve the survival and quality of life for patients who have unmet medical needs, has scheduled a conference call to discuss its Q2 results and to provide an update on its drug development pipeline. The call is scheduled for Aug. 12, 2021, at 5:30 […]

InvestorNewsBreaks

InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Announces Gastrointestinal Cancer Study Dosing Has Begun

August 4, 2021

Processa Pharmaceuticals (NASDAQ: PCSA), a clinical-stage biopharmaceutical company developing products to improve the survival and quality of life for patients who have unmet medical needs, has dosed the first patient in its PCS6422 study. The study is a phase 1b dose-escalation evaluation of the safety and pharmacokinetics of fixed-dose PCS6422 with escalating doses of capecitabine administered […]

InvestorNewsBreaks

InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) to Present at ‘Zooming with LD Micro’

July 27, 2021

Processa Pharmaceuticals (NASDAQ: PCSA), a biopharmaceutical company developing products to improve the survival and/or quality of life for patients who have unmet medical needs, today announced that it will be presenting at the upcoming “Zooming with LD Micro” virtual investor event. Processa’s presentation is scheduled to begin at 12:00 p.m. ET on Thursday, July 29, […]

InvestorNewsBreaks

InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Plans Presentation at Unique Access to Giving Virtual Investor Conference

July 6, 2021

Processa Pharmaceuticals (NASDAQ: PCSA), a clinical-stage biopharmaceutical company developing products to improve the survival and quality of life for patients who have unmet medical needs, is slated to present at the upcoming Access to Giving virtual conference. The conference is scheduled for July 14, 2021; PCSA’s presentation will begin at 10:30 a.m. ET. PCSA CEO […]

InvestorNewsBreaks

InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) to Participate in Access to Giving Virtual Investor Conference

June 23, 2021

Processa Pharmaceuticals (NASDAQ: PCSA), a clinical-stage biopharmaceutical company developing products to improve the survival and quality of life for patients who have unmet medical needs, will participate in the Access to Giving investor conference. The conference, scheduled for July 13–15, 2021, is the first of its kind focused on investor education and advocacy. More than […]

InvestorNewsBreaks

InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Announces Strategic Licensing Agreement

June 17, 2021

Processa Pharmaceuticals (NASDAQ: PCSA), a clinical-stage biopharmaceutical company developing products to improve the survival and quality of life for patients who have unmet medical needs, has entered into a licensing agreement with Ocuphire Pharma Inc. (NASDAQ: OCUP). Under the agreement, Processa has an exclusive worldwide license (excluding China) to develop, manufacture, use, commercialize and sublicense […]

InvestorNewsBreaks

InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) to Join Russell Microcap(R) Index

June 9, 2021

Processa Pharmaceuticals (NASDAQ: PCSA), a clinical-stage biopharmaceutical company developing products to improve the survival and quality of life for patients who have unmet medical needs, announced that it is set to join the Russell Microcap(R)Index. The company noted that it is scheduled to make the move at the conclusion of the 2021 Russell indexes annual […]

InvestorNewsBreaks

InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Announces Participation in Upcoming LD Micro Virtual Investor Conference

June 8, 2021

Processa Pharmaceuticals (NASDAQ: PCSA), a clinical-stage biopharmaceutical company developing products to improve the survival and quality of life for patients who have unmet medical needs, will participate in the LD Micro Virtual Investor Conference. The conference is slated for June 9, 2021. PCSA management will present during the conference. PCSA’s actual presentation is scheduled as […]

InvestorNewsBreaks

InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Announces Participation in Upcoming Investor Conferences

May 26, 2021

Processa Pharmaceuticals (NASDAQ: PCSA), a clinical-stage biopharmaceutical company developing products to improve the survival and quality of life for patients who have unmet medical needs, has announced that executive management personnel will be participating in two investor conferences, both scheduled to take place in June. Company officials will be at the Craig-Hallum Virtual Institutional Investor Conference, […]

InvestorNewsBreaks

InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Announces Phase 2 PCS499 Trial Has First Dosed Patient

May 21, 2021

Processa Pharmaceuticals (NASDAQ: PCSA), a clinical-stage biopharmaceutical company developing products to improve the survival and/or quality of life for patients who have unmet medical needs, has dosed its first patient in its PCS499 trial; the dosing took place at the Clinical Research Center of the Carolinas. The trial, which is currently enrolling patients, is designed […]

InvestorNewsBreaks

InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Announces Participation in Upcoming Investor Conferences

May 19, 2021

Processa Pharmaceuticals (NASDAQ: PCSA), a clinical-stage biopharmaceutical company developing products to improve the survival and/or quality of life for patients who have unmet medical needs, has announced that key management personnel will participate in two upcoming investor conferences. PCSA executives will present at the Oppenheimer Rare & Orphan Disease Summit, which is scheduled for May […]

InvestorNewsBreaks

InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Releases Q1 2021 Financial, Corporate Report

May 14, 2021

Processa Pharmaceuticals (NASDAQ: PCSA), a clinical-stage biopharmaceutical company developing products to improve the survival and quality of life for patients who have unmet medical needs, has reported its financial and corporate results for the first quarter of 2021, the period ended March 31, 2021. In the report, PCSA noted that its clinical drug pipeline is […]

InvestorNewsBreaks

InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) to Host Conference/Webcast to Discuss Q1 Results, Provide Clinical Pipeline Update

May 7, 2021

Processa Pharmaceuticals (NASDAQ: PCSA), a clinical-stage biopharmaceutical company developing products to improve the survival and/or quality of life for patients who have unmet medical needs, today announced that it will host a conference call and live webcast to discuss its first quarter 2021 results and provide an update on its clinical pipeline. The event is […]

No ResultsNo content matches your search/filter.

 

 

 

Get Started with InvestorWire

To distribute a release in the next 24 hours. Contact our client services team.

(310) 299-1717

Distribute a press release. Submit your release to get started.

Submit Press Release

Set up a Live demonstration. Schedule a date and time that works for you.

Schedule a LIVE Demo

Press Distribution

Explore Press Distribution Solutions

All releases include an unlimited word count* with full wire-grade syndication, our press release enhancement service, and a follow-up InvestorNewsBreak article distributed to thousands of editorial syndication partners.

Discover Add-on Solutions

Increase the impact of your achievements by adding these exclusive solutions from InvestorWire, delivered in conjunction with the InvestorBrandNetwork (IBN).